2- ((1- (3,5- dichlorobenzenesulfonyl)pyrrolidine- 2- carbonyl)amino)- 4- (4- methyl- 2- (methyl- (2- (4- (3- o- tolylureido)phenyl)acetyl)amino)pentanoylamino)butyric acid

an integrin alpha4beta1 inhibitor; structure in first source

Also Known As:

BIO 5192; BIO-5192; BIO5192

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - 2-((1-(3,5-dichlorobenzenesulfonyl)pyrrolidine-2-carbonyl)amino)-4-(4-methyl-2-(methyl-(2-(4-(3-o-tolylureido)phenyl)acetyl)amino)pentanoylamino)butyric acid: 4
Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - Phenylurea Compounds: 1
      - 2-((1-(3,5-dichlorobenzenesulfonyl)pyrrolidine-2-carbonyl)amino)-4-(4-methyl-2-(methyl-(2-(4-(3-o-tolylureido)phenyl)acetyl)amino)pentanoylamino)butyric acid: 4
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenylurea Compounds: 1
        2-((1-(3,5-dichlorobenzenesulfonyl)pyrrolidine-2-carbonyl)amino)-4-(4-methyl-2-(methyl-(2-(4-(3-o-tolylureido)phenyl)acetyl)amino)pentanoylamino)butyric acid: 4

Experts

1.	Adams, S P: 2 articles (02/2005 - 06/2003)
2.	Chen, L L: 2 articles (02/2005 - 06/2003)
3.	Cornebise, M: 2 articles (02/2005 - 06/2003)
4.	Dolinski, B M: 2 articles (02/2005 - 06/2003)
5.	Gill, A: 2 articles (02/2005 - 06/2003)
6.	Giza, K: 2 articles (02/2005 - 06/2003)
7.	Lee, W-C: 2 articles (02/2005 - 06/2003)
8.	Leone, D R: 2 articles (02/2005 - 06/2003)
9.	Lobb, R R: 2 articles (02/2005 - 06/2003)
10.	Nickerson-Nutter, C: 2 articles (02/2005 - 06/2003)

Related Diseases

1.	Acute Disease 12/15/2003 - "Interestingly, BIO 5192 treatment begun at the peak of acute disease accelerated entrance into disease remission and inhibited relapses, but treatment removal again exacerbated disease. "
2.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 02/01/2005 - "The PEGylated compound was efficacious in a rat model of experimental autoimmune encephalomyelitis at a 30-fold lower molar dose than the parent compound and required only a once-a-week dosing regimen compared with a daily treatment for BIO5192. " 06/01/2003 - "An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis." 06/01/2003 - "Here we evaluated the biochemical, pharmacological, and pharmacodynamic properties and efficacy in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, of two types of alpha 4 beta 1 inhibitors, the anti-rat alpha 4 monoclonal antibody TA-2 and the small molecule inhibitor BIO5192 [2(S)-[[1-(3,5-dichloro-benzenesulfonyl)-pyrrolidine-2(S)-carbonyl]-amino]-4-[4-methyl-2(S)-(methyl-[2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl]-amino)-pentanoylamino]-butyric acid]. "
3.	Disease Progression 12/15/2003 - "BIO 5192 administered one week after peptide priming (ie, before clinical disease onset) delayed the clinical disease onset but led to severe disease exacerbation upon treatment removal. "
4.	Multiple Sclerosis 06/01/2003 - "Here we evaluated the biochemical, pharmacological, and pharmacodynamic properties and efficacy in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, of two types of alpha 4 beta 1 inhibitors, the anti-rat alpha 4 monoclonal antibody TA-2 and the small molecule inhibitor BIO5192 [2(S)-[[1-(3,5-dichloro-benzenesulfonyl)-pyrrolidine-2(S)-carbonyl]-amino]-4-[4-methyl-2(S)-(methyl-[2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl]-amino)-pentanoylamino]-butyric acid]. "
5.	Hyperalgesia 12/01/2008 - "BIO5192 treatment also decreased mechanical allodynia elicited from the trunk and hind paw by up to 35%. "

Related Drugs and Biologics

1.	Integrin alpha4beta1 (VLA-4)
2.	Butyric Acid (Butanoic Acid)
3.	Peptides (Polypeptides)
4.	Monoclonal Antibodies
5.	pyrrolidine